CS
ALXN

Candriam SCA’s Alexion Pharmaceuticals ALXN Stock Holding History

Candriam SCA’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-503,510
Closed -$92.5M – 935
2021
Q2 		$92.5M Sell
503,510
-106,772
-17% -$18.3M 0.63% 33
2021
Q1 		$91.6M Hold
610,282
– – 0.76% 22
2020
Q4 		$95.4M Buy
610,282
+47,210
+8% +$6.07M 0.75% 22
2020
Q3 		$64.4M Sell
563,072
-1,027
-0.2% -$111K 0.61% 31
2020
Q2 		$63.3M Sell
564,099
-11,695
-2% -$1.24M 0.67% 27
2020
Q1 		$60.9M Hold
575,794
– – 0.67% 25
2019
Q4 		$62.3M Sell
575,794
-55,972
-9% -$5.99M 0.67% 25
2019
Q3 		$61.9M Buy
631,766
+66,533
+12% +$7.5M 0.82% 20
2019
Q2 		$73.7M Buy
565,233
+181
+0% +$23.3K 0.92% 17
2019
Q1 		$76.4M Sell
565,052
-60,845
-10% -$7.57M 0.98% 17
2018
Q4 		$60.9M Buy
625,897
+145,077
+30% +$17.1M 0.94% 17
2018
Q3 		$66.8M Buy
480,820
+186,778
+64% +$23.4M 0.89% 18
2018
Q2 		$36.5M Buy
294,042
+32,923
+13% +$3.85M 0.58% 33
2018
Q1 		$29.1M Sell
261,119
-48,672
-16% -$5.82M 0.5% 36
2017
Q4 		$37M Buy
309,791
+40,873
+15% +$4.98M 0.64% 28
2017
Q3 		$37.7M Buy
268,918
+46,820
+21% +$6.36M 0.66% 25
2017
Q2 		$27M Buy
222,098
+12,701
+6% +$1.48M 0.51% 35
2017
Q1 		$25.4M Buy
209,397
+15,797
+8% +$2.04M 0.49% 39
2016
Q4 		$23.7M Buy
193,600
+29,033
+18% +$3.55M 0.54% 42
2016
Q3 		$20.2M Buy
164,567
+21,156
+15% +$2.72M 0.49% 46
2016
Q2 		$16.7M Buy
143,411
+6,017
+4% +$854K 0.44% 63
2016
Q1 		$19M Buy
+137,394
New +$20.2M 0.48% 49
2015
Q4 		– Sell
-174,944
Closed -$27.4M – 642
2015
Q3 		$27.4M Sell
174,944
-14,083
-7% -$2.57M 0.67% 26
2015
Q2 		$34.2M Sell
189,027
-10,930
-5% -$1.89M 0.71% 24
2015
Q1 		$34.7M Buy
199,957
+9,819
+5% +$1.78M 0.7% 29
2014
Q4 		$35.2M Buy
+190,138
New +$35.2M 0.74% 28

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Candriam SCA's ALXN Position: Q3 2021 in Review

Candriam SCA sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 503,510 shares — an estimated $92.5M sold.

Candriam SCA first reported a position in ALXN in Q4 2014 and held it in 26 quarters. The position peaked at $95.4M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Candriam SCA reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Candriam SCA sold 503,510 Alexion Pharmaceuticals shares in Q3 2021, an estimated $92.5M.
  • Candriam SCA first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 26 quarters.
  • Candriam SCA's Alexion Pharmaceuticals position peaked at $95.4M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.